AZD5718 IR tablet + AZD5718 oral suspension + Rosuvastatin tablet
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Risk Coronary Artery Disease
Conditions
High Risk Coronary Artery Disease
Trial Timeline
Dec 20, 2016 → Mar 1, 2017
NCT ID
NCT02963116About AZD5718 IR tablet + AZD5718 oral suspension + Rosuvastatin tablet
AZD5718 IR tablet + AZD5718 oral suspension + Rosuvastatin tablet is a phase 1 stage product being developed by AstraZeneca for High Risk Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02963116. Target conditions include High Risk Coronary Artery Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02963116 | Phase 1 | Completed |
Competing Products
20 competing products in High Risk Coronary Artery Disease